Aug. 27 at 8:35 PM
$PFE Recent Pipeline and Regulatory Updates
Lyme Disease Vaccine: The European Medicines Agency (EMA) validated the Marketing Authorization Application for Pfizer and Valneva's joint Lyme disease vaccine candidate.
Prostate Cancer Review: The FDA granted Priority Review for Pfizer's Talzenna combined with Xtandi to treat metastatic prostate cancer.
Bladder Cancer Approval: The FDA approved Padcev plus Keytruda for muscle-invasive bladder cancer.
Vitiligo Results: Pfizer announced positive Phase 3 topline results for Litfulo in patients suffering from nonsegmental vitiligo.
Financial and Market Position
Guidance: Management raised the 2026 revenue guidance midpoint by
$500 million following steady non-COVID revenue recovery.
Dividends: The company declared its third-quarter 2026 dividend while balancing cost-cutting initiatives to offset declining pandemic-era product sales.